A common and low-cost antidepressant can successfully treat fatigue associated with long COVID, according to a new study.

Co-led by researchers from McMaster University in Ontario, the study found that the drug fluvoxamine, which is commonly sold under the name Luvox, significantly reduced fatigue symptoms in a clinical trial of 399 adults with long COVID. It is one of the first times a medication has been shown to effectively treat the condition.

“This is an important step forward for patients who have been desperate for evidence‑based options,” senior author and McMaster University professor Edward Mills said in a news release.

“Fluvoxamine showed consistent and meaningful benefits, and because it’s already widely used and well understood, it has clear potential for clinical use.”